BGLC vs NSC · rev $99.0K vs P/E 18, rev $6.46B
BioNexus Gene Lab Corp Common stock (BGLC) versus Norfolk Southern Corporation (NSC) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported NSC revenue for 2026-06-30 was $6.46B. Net income was $1.28B. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
BGLC currently screens at market cap $6.1M. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Not investment advice. Open the BGLC and NSC stock pages for the full models.
Not investment advice.